Moderna logo

ModernaNASDAQ: MRNA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 December 2018

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$14.38 B
-90%vs. 3y high
95%vs. sector
-vs. 3y high
-vs. sector
-91%vs. 3y high
43%vs. sector
-79%vs. 3y high
46%vs. sector

Price

pre-market | 7 min ago
$37.36+$0.10(+0.27%)

Dividend

No data over the past 3 years
$1.85 B$1.03 B
$1.85 B$13.00 M

Analysts recommendations

Institutional Ownership

MRNA Latest News

BioNTech and Moderna at vanguard of new treatment wave - but which is best?
proactiveinvestors.co.uk19 November 2024 Sentiment: POSITIVE

The mRNA technology that helped create COVID-19 vaccines quickly is now leading to significant changes in medicine. Berenberg suggests that this new method could change how we treat various illnesses, especially cancer and infectious diseases.

Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination
benzinga.com18 November 2024 Sentiment: POSITIVE

Last week, shares of some major vaccine companies in Europe and the U.S. dropped after Robert F. Kennedy Jr. was nominated to head the Department of Health and Human Services.

Cramer's Mad Dash: Moderna gets upgrade from HSBC
youtube.com18 November 2024 Sentiment: POSITIVE

Jim Cramer from CNBC shares the most recent updates about Moderna.

Moderna, Inc. (MRNA) Guggenheim's Inaugural Healthcare Innovation Conference (Transcript)
seekingalpha.com15 November 2024 Sentiment: NEUTRAL

Moderna, Inc. (NASDAQ:MRNA) will be participating in Guggenheim's first Healthcare Innovation Conference on November 12, 2024, at 10:00 AM ET. The company will be represented by Stephen Hoge, the President. Evan Wang, a senior biotech analyst at Guggenheim, will also be part of the conference.

Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary
fastcompany.com15 November 2024 Sentiment: NEGATIVE

Stock prices for some of the biggest drug companies in the U.S. dropped yesterday after President-elect Donald Trump chose Robert F. Kennedy Jr. to be the secretary of the Department of Health and Human Services (HHS).

Moderna And Other Vaccine Maker Stocks Tumble After Trump Taps RFK Jr. As HHS Head
forbes.com14 November 2024 Sentiment: NEGATIVE

Shares of vaccine companies like Moderna, Pfizer, and Novavax dropped significantly just before the market closed on Thursday. This decline followed news that President-elect Donald Trump might choose Robert F. Kennedy Jr., who is known for his skepticism about vaccines, to lead the Department of Health and Human Services.

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS
marketwatch.com14 November 2024 Sentiment: NEGATIVE

On Thursday, shares of companies that produce vaccines dropped after it was announced that President-elect Donald Trump had chosen Robert F. Kennedy Jr., a known vaccine skeptic and former presidential candidate, to head the U.S. Department of Health and Human Services.

Nutcracker Therapeutics Introduces CRDMO Precision Biomanufacturing Solutions for mRNA Drug Developers
businesswire.com12 November 2024 Sentiment: POSITIVE

EMERYVILLE, Calif.--(BUSINESS WIRE)--CRDMO offers specialized services for various mRNA uses, such as producing small amounts for personalized cancer vaccines (PCVs).

Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
benzinga.com08 November 2024 Sentiment: POSITIVE

On Thursday, Moderna Inc. MRNA announced that its revenue for the third quarter was $1.83 billion, which is higher than the expected $1.25 billion.

Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and Older
accesswire.com08 November 2024 Sentiment: POSITIVE

mRESVIA is Moderna's second product approved in Canada and is the first mRNA vaccine for RSV, available in single-dose pre-filled syringes. Canada is the fourth region to approve mRESVIA, following the U.S., Europe, and Qatar. Stéphane Bancel, CEO of Moderna, stated that this approval highlights the potential of mRNA technology to tackle major public health issues like RSV, especially for older adults.

What type of business is Moderna?

Moderna, Inc. is an American biotechnology company focused on the development of drugs and vaccines based on messenger RNA (mRNA). The company was founded in 2010, with its headquarters located in Cambridge, Massachusetts. Moderna, Inc. has built a platform for the identification and development of new drugs based on mRNA. The platform is based on accumulated knowledge and continuous advancements in the field of fundamental and applied mRNA science, mRNA delivery to target tissues, and manufacturing processes for producing potential mRNA-based drugs.

What sector is Moderna in?

Moderna is in the Healthcare sector

What industry is Moderna in?

Moderna is in the Biotechnology industry

What country is Moderna from?

Moderna is headquartered in United States

When did Moderna go public?

Moderna initial public offering (IPO) was on 07 December 2018

What is Moderna website?

https://www.modernatx.com

Is Moderna in the S&P 500?

Yes, Moderna is included in the S&P 500 index

Is Moderna in the NASDAQ 100?

Yes, Moderna is included in the NASDAQ 100 index

Is Moderna in the Dow Jones?

No, Moderna is not included in the Dow Jones index

When was Moderna the previous earnings report?

No data

When does Moderna earnings report?

The next expected earnings date for Moderna is 21 February 2025